Home Bladder Cancer Combos & Biomarkers will Shape the Future of Bladder Cancer Immunotherapy

Combos & Biomarkers will Shape the Future of Bladder Cancer Immunotherapy

615
0
Bladder Cancer

Onclive reports that although multiple checkpoint inhibitors have been introduced into the bladder cancer treatment paradigm during the past several years, their use in the malignancy remains an unfolding story, according to Joaquim Bellmunt, MD, PhD. The future, Bellmunt believes, is in identifying biomarkers and exploring combination therapy. Bellmunt, a leading investigator in the field, recapped developments in bladder cancer during the 3rd AnnualInternational Congress on Immunotherapies in Cancer™ that Physicians’ Education Resource® (PER®) sponsored in New York, New York, in December 2018.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.